Affirm and Moore Capital Management extend long-term capital partnership
SAN FRANCISCO--(BUSINESS WIRE)--Affirm (NASDAQ: AFRM), the payment network that empowers consumers and helps merchants drive growth, and the Moore Specialty Credit ("MSC") Platform, the Private Asset Backed Finance ('ABF') platform of Moore Capital Management, LP ('Moore'), a global private investment management firm, today announced an extension of their long-term capital partnership through May 2027.
The expansion builds upon Affirm and MSC's longstanding collaboration, which will surpass a decade through their latest forward flow agreement. As Affirm's first loan buyer, Moore has supported Affirm's efforts to increase access to flexible and transparent payment options since 2017 through multiple funding channels and partnerships.
"Our deep relationship with Affirm has allowed us to see firsthand their differentiated approach to driving positive credit outcomes,' said Erik Siegel, CIO of the Moore Specialty Credit Platform. 'We look forward to continuing to support Affirm as it continues to generate quality assets that deliver attractive risk-adjusted returns.'
Moore has invested nearly $5 billion in Affirm's assets since beginning its capital partnership in 2017. This includes multiple forward flow partnerships with Affirm and supporting the Company's asset-backed securitizations through Moore's Private ABF platform, Moore Specialty Credit.
'We appreciate Moore's long-term support as one of Affirm's earliest capital partners, especially their analytical expertise and thoughtful approach to structuring,' said Brooke Major-Reid, Chief Capital Officer at Affirm. 'The expansion of our collaboration further validates our strategy of investing in foundational relationships as we extend responsible access to credit without any late fees or hidden charges.'
Affirm empowers consumers with a transparent and flexible way to pay over time without any late or hidden fees. The company generated over $33 billion in gross merchandise volume (GMV) for the last twelve months ending March 31, 2025. With a diverse and durable funding model across multiple channels, Affirm's total funding capacity grew to $23.3 billion as of March 31, 2025, marking the ninth consecutive quarter that funding capacity increased. As a scaled and programmatic issuer, Affirm has issued 24 asset-backed securitizations totaling $12.25 billion with participation from over 150 unique capital partners across institution types, including: alternative asset managers, insurance companies, pension funds, sovereign wealth funds, hedge funds, and banks.
About Affirm
Affirm's mission is to deliver honest financial products that improve lives. By building a new kind of payment network—one based on trust, transparency, and putting people first—we empower millions of consumers to spend and save responsibly, and give thousands of businesses the tools to fuel growth. Unlike most credit cards and other pay-over-time options, we never charge any late or hidden fees. Follow Affirm on social media: LinkedIn | Instagram | Facebook | X.
About Moore Capital Management
Moore Capital Management is the global private investment management firm of Louis Bacon. Moore Capital invests in the public global financial markets and real estate, private lending and private equity markets.
AFRM-PA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Seeking a Cure for Sickly Corporate Governance at SinoVac
Chinese SinoVac Biotech Ltd. (Nasdaq: SVA) shares have been frozen since 2019 amid shareholder disputes when market cap was about $500 million SinoVac developed a wildly successful Covid vaccine and has over $10 billion in cash on balance sheet but investors have had no dividends or liquidity Current board is fending off a competing slate of directors supported by the founder/CEO along with large investors representing over 31% of shares outstanding Current board made announcements that may have contributed to the resignation of Grant Thornton, preventing filing of 2024 financials Accounting and governance experts told CorpGov SinoVac will struggle to secure a major auditor with current board Professor Charles Elson told CorpGov that potentially 'precipitating' the departure of Grant Thornton 'is about as bad as it gets' and raises questions about corporate governance under the current board Both parties plan to pay a $55/share dividend, but SinoVac has significantly more value that will require trading to resume for investors to benefit Shareholders will decide on whether to keep or replace board at a meeting on July 8 By John Jannarone Picking a winner in biotech stocks is hard enough as it is. Imagine investing in a small company that became one of the biggest suppliers of Covid vaccines in China, resulting in a multibillion-dollar windfall and potential 25x rise value, only to see the shares frozen for years. The question now: Can a new board of directors do better at unlocking value? Meet Chinese SinoVac Biotech Ltd. (SVA), a Nasdaq-listed company that's been embroiled in shareholder disputes for many years. About a year before the first whispers about Covid circulated, the stock was frozen following an extremely rare occurrence: A so-called poison pill was activated, triggering a flood of new shares issued to some shareholders and a trading halt on the exchange. The shares, while remaining listed, haven't traded since early 2019. The following year, the company successfully developed a Covid vaccine that was widely used – especially in China – resulting in tremendous financial success. All told, the company has about $10.3 billion in cash, which equates to roughly $140 a share, excluding any value assigned to the operating business, according to SAIF Partners, the company's largest shareholder with a 15% stake. The fate of the company – and its cash hoard – now depends on a shareholder vote on July 8 to decide whether to replace the current board. The challenger group, led by SAIF Partners, includes the SinoVac Founder and CEO Weidong Yin along with Vivo Capital and Advantech Capital, which hold 16% stake between the two investment firms. Spokespeople for SAIF, Advantech and Vivo all referred CorpGov to existing statements and declined to comment further. On the other side, supporting the current board, is Chairman Chiang Li and his 1Globe Capital family office along with two investment firms, OrbiMed, and Heng Ren Partners. A company spokesperson also directed CorpGov to public statements already issued. Unfortunately, the current board hasn't made much progress towards unfreezing the shares – perhaps the most important short-term goal. Quite to the contrary, the board may have contributed to the resignation of its auditor, Grant Thornton, after announcing it was 'assessing certain corporate actions taken by the former board of directors.' Grant Thornton said in a letter to SinoVac that one reason for its resignation was that the board's announcement introduced 'uncertainty' and it would not be able to sign off on the company's 2024 financial statements. For its part, the board has argued that Grant Thornton's departure was unrelated to any of its action. A company filing cited Grant Thornton's letter which stated that its 'resignation was not the result of any disagreement with the [Company's current board of directors], the Company or management.' Regardless of which combination of factors triggered Grant Thornton's departure, the loss of a top-tier firm may mean the company won't find another major accounting firm to sign off on its numbers, putting the company's listing in further jeopardy. 'At this point, the board looks like it's up to something,' an accounting expert who asked not to be named told CorpGov. 'Other firms will be reluctant until that's cleared up.' Indeed, the current board may have lost broader credibility, according to Charles Elson, Founding Director, Weinberg Center for Corporate Governance at the University of Delaware. 'It doesn't reflect well on any board that would allow an auditor to resign – what's worse is if a board precipitates the departure. That doesn't seem to be in the interest of the company or shareholders – the fiduciary duty of the board,' Mr. Elson told CorpGov. 'You have to ask if it was done to help the company or in the self-interest of the directors.' Professor Elson noted that the company has performed well with a highly successful drug and that its operations aren't the concern at hand. 'It goes beyond a performance issue and is a governance issue they are facing,' he said. The current board has also been eroded down to just four members after multiple departures. One of those of note is Pengfei Li, who was sentenced to prison after charges including embezzlement and forging government documents and seals apparently related to his attempt to seize control of a SinoVac subsidiary. Interestingly, the challenger group isn't trying to wipe out all existing directors. The slate actually includes two of the current four board members, Chiang Li, who is himself a major investor in the company, along with Yuk Lam Lo who was elected in a previous shareholder vote. While a resumption of trading may be the best outcome for shareholders seeking liquidity, there is also discussion of a massive $55-a-share dividend, which would be welcome for those who have been waiting years without seeing a dime. It appears that both boards support that dividend and more, but discussion of it didn't begin until recently when SAIF began making a stir. What's more, there is no reason why the dividend couldn't be paid before the July meeting – even if the shares remain halted. Finally, it's important to look at SinoVac as a successful company – well beyond Covid. The company had $440 million in sales in 2023, and $121 million in in the first half of 2024 (the business is highly seasonal and financials for the second half of 2024 have not yet been filed), with revenue coming from a variety of non-covid drugs and geographies. While the company's cash value may be around $140 per share, the real job of the new board is to focus on getting the company focused on its operations – rather than fights and lawsuits. After so many years, investors who vote for board change may finally reap the rewards of SinoVac's underlying success. Contact: CorpGov Editor@ The post Seeking a Cure for Sickly Corporate Governance at SinoVac appeared first on CorpGov.
Yahoo
33 minutes ago
- Yahoo
Don't Sweat Duolingo Stock's June Doldrums
The shares of language learning platform Duolingo Inc (NASDAQ:DUOL) are down 2.7% at $411.54 at last glance, looking to extend their recent slide. hung around its May 14 record high of $544.93 for a few weeks before beginning a sharp descent lower, marking only three positive days since June 6. On the side of the bulls, however, DUOL is still up 26.9% in 2025, and currently flashing a historically bullish signal. Per Schaeffer's Senior Quantitative Analyst Rocky White, the recent pullback has Duolingo stock within striking distance of its 80-day moving average. More specifically, the stock is within 0.75 of the trendline's 20-day average true range (ATR) after spending at least 80% of the last 10 days and 80% of the last two months above it. Within these parameters, six other signals occurred in the past three years. DUOL was higher one month later 67% of the time after those instances, averaging a large 15.7% gain. A move of similar magnitude would have the shares back up above $476, recovering a good portion of its recent losses. Also in the stock's favor, its 14-day relative strength index (RSI) of 13.2 sits firmly in "oversold" territory, pointing to a potential short-term bounce. An unwinding of pessimism amongst options traders could provide tailwinds as well, per DUOL's 50-day put/call volume ratio of 1.83 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which ranks higher than 98% of readings from the past year.
Yahoo
44 minutes ago
- Yahoo
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of 10 AI stocks that will skyrocket. Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock. The revision comes in response to the company's recent strategic updates, including a restructured pipeline, workforce reduction, and revised financial guidance. In a note to investors, the firm cited Recursion's recent decision to prioritize core programs and streamline operations, including a 20% reduction in headcount, as key drivers for the model revision. The company also issued updated guidance on cash burn, signaling tighter capital discipline as it focuses on long-term sustainability. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. Morgan Stanley noted that while the moves could support operational focus and extend cash runway, they also reflect the challenges of advancing a broad pipeline under current market conditions. The firm views the restructuring as a necessary, though measured, step to align resources with the most promising opportunities in the portfolio. Despite the reduced target, Morgan Stanley's Equal Weight rating suggests a neutral stance, with the belief that both upside and downside risks are now more balanced given the new strategy and cost structure. Recursion Pharmaceuticals, Inc. (RXRX) is recognized for its advanced use of computational methods and machine learning to accelerate drug discovery. The firm combines biology, chemistry, and automation with data-driven approaches to identify potential treatments faster and more efficiently than traditional methods. While we acknowledge the potential of RXRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Small Cap Tech Stocks With Biggest Upside Potential and 7 Most Popular AI Penny Stocks Under $5 To Avoid. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
